JAMA (2016) 316(5):5008
The missed-pill rule (which applies to every GLP-1) Nausea is the most common side effect across the entire GLP-1 class about 1 in 3 patients on Wegovy report it, and rates are higher during the first few weeks and after dose increases
Peptide Research Deep Dives In-depth overviews, mechanism breakdowns, compound comparisons, and laboratory method guides all sourced from peer-reviewed literature
Thus, the growth in GLP-1 RA prescribing among patients with PCOS may reflect a combination of general expansion in GLP-1 RA use and the high prevalence of metabolic indications in this population
Improper sanitation, which can increase the risk of infection
Montero, et al., 2024), though the medications are still financially out of reach for many U.S